The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest adalimumab, infliximab and etanercept biosimilars market share.

The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $4.76 billion in 2022 to $6.24 billion in 2023 at a compound annual growth rate (CAGR) of 31.1%. The adalimumab, infliximab and etanercept biosimilars market is expected to grow from $25.73 billion in 2027 at a CAGR of 42.5%.

Major Driver In The Adalimumab, Infliximab And Etanercept Biosimilars Market ­– Rise In Patent Expiry Of Branded Biologic Drugs
For example, once the patent on the branded medicine Remicade expired, the FDA approved inflectra, produced by Hospira (a Pfizer Inc. firm), for the treatment of numerous autoimmune disorders such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. Similarly, Amgen’s Enbrel saw its patent expire in the EU, and with the expiration of the patent, the European Commission authorised Benepali (an Enbrel biosimilar). Humira’s patent lapsed, and biosimilars were released to the market. Hulio, the sixth Humira biosimilar, was just approved by the FDA (July 2020). As a result, the patent expiration of branded biologic medications like Humira, Enbrel, and Remicade will fuel the biosimilar business.

View More On The Adalimumab, Infliximab And Etanercept Biosimilars Market Report 2023 –
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Key Adalimumab, Infliximab And Etanercept Biosimilars Market Segments
1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)
2) By Application: Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Recent Adalimumab, Infliximab And Etanercept Biosimilars Market Trend – Adopting Brand-Name Versions Of Biosimilar Drugs
Brand-name versions of biosimilar medications are expensive, and they are now being replaced with biosimilar counterparts when their patents expire. In recent years, the price of branded biological medications has nearly doubled. For example, the top-selling medicine, Humira, will cost more than $72,000 in 2020. The transition to low-cost biosimilar medications is mostly due to the absence of clinically significant differences in safety and efficacy between biosimilars and original biologics. After the patent on the original adalimumab medicine, Humira, expired in October 2018, the Danish health-care system moved nearly exclusively to adalimumab biosimilars. The move to biosimilars resulted in an 82% decrease in drug expenses.

Adalimumab, Infliximab And Etanercept Biosimilars Market Prominent Players
Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd., and Glenmark Pharmaceuticals.

Request A Sample Of The Global Adalimumab, Infliximab And Etanercept Biosimilars Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

The Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023  provides a comprehensive overview on the adalimumab, infliximab and etanercept biosimilars market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Adalimumab, infliximab, and etanercept biosimilars are a new family of drugs that work by inhibiting the inflammatory mediator tumour necrosis factor-alpha (TNF-alpha). An infliximab biosimilar is a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-alpha). It is used to treat immune system diseases.

View More Related Reports –
Biosimilars Global Market Report 2023
Oral Biologics And Biosimilars Global Market Report 2023
Oncology Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model